Company intelligence
Cipla
About Cipla
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.
Verified activity
Signals from Cipla
5 published signals
Presence & Recognition
Cipla represented at the 2026 ERS Congress in Barcelona, attended by the Cipla Spain Marketing team, Regional Head Jortin George, and Medical Affairs team lead Dr. Jaideep Gogtay.
Reported by Jose Ramon Lopez
Presence & Recognition
Cipla has been honoured with the Exemplary Supply Chains Enterprise Award 2026 at the 8th Celerity Supply Chain Tribe Conference & Awards 2026
Reported by Cipla
Partnerships
Cipla announced an exclusive partnership with Qilu Pharmaceutical for the licensing and supply of biosimilar to Keytruda (Pembrolizumab) in the US.
Reported by Cipla
Products & Services
Cipla USA announced the launch of Pomalidomide Capsules, a generic of Pomalyst, across all strengths.
Reported by Cipla
Strategy & Corporate Development
Cipla and SBP Group signed an exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102) for patients with breast cancer across India, South Africa, and emerging markets.
Reported by Cipla